Stay updated with breaking news from Study Author. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure patients with mildly reduced and preserved ejection fraction.
Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late-breaking research presented in a Hot Line session today at ESC Congress 2022.
A restrictive oxygenation target in comatose patients resuscitated after out-of-hospital cardiac arrest does not worsen survival or neurological outcome compared with a liberal target, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.
Nine in ten people do not get a good night's sleep, according to research presented at ESC Congress 2022.
Sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with heart failure and mildly reduced or preserved ejection fraction, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.